Home Osmotica Announces FDA Acceptance Of Filing For Ontinua ER For Alleviation Of Spasticity Resulting From Multiple Sclerosis And Strong Advancement In The Clinical Program For Osmolex ER
 

Keywords :   


Osmotica Announces FDA Acceptance Of Filing For Ontinua ER For Alleviation Of Spasticity Resulting From Multiple Sclerosis And Strong Advancement In The Clinical Program For Osmolex ER

2015-09-30 08:56:43| drugdiscoveryonline News Articles

Osmotica Pharmaceutical Corp. (privately held), a global specialty pharmaceutical corporation developing best-in-class therapeutics for the treatment of CNS diseases, announced recently that the New Drug Application (NDA) for OntinuaTM ER has been accepted for filing by the U.S. Food and Drug Administration (FDA)

Tags: the for er program

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
28.03FTX's Sam Bankman-Fried sentenced to 25 years
28.03Pork producers donate 35,000 pounds of Dailys bacon to Utah Food Bank
28.03Post-Brexit tax to hit UK car exports to Canada
28.03Webinar series to focus management of beef on dairy crossbreds
28.03Secret papers show Post Office knew case was false
28.03LOccitane Travel Retail Debuts New Bodycare Range From Sol de Janeiro With Paris Pop-Up
28.03Understanding cattle grazing personalities may foster sustainable rangelands
28.03Bill seeks fairer market prices for Livestock Indemnity Program
More »